175 related articles for article (PubMed ID: 19729853)
1. Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer's disease.
Fukuda M; Kanou F; Shimada N; Sawabe M; Saito Y; Murayama S; Hashimoto M; Maruyama N; Ishigami A
Biomed Res; 2009 Aug; 30(4):227-33. PubMed ID: 19729853
[TBL] [Abstract][Full Text] [Related]
2. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype.
Montine KS; Reich E; Neely MD; Sidell KR; Olson SJ; Markesbery WR; Montine TJ
J Neuropathol Exp Neurol; 1998 May; 57(5):415-25. PubMed ID: 9596412
[TBL] [Abstract][Full Text] [Related]
3. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease.
Markesbery WR; Lovell MA
Neurobiol Aging; 1998; 19(1):33-6. PubMed ID: 9562500
[TBL] [Abstract][Full Text] [Related]
4. Role of by-products of lipid oxidation in Alzheimer's disease brain: a focus on acrolein.
Singh M; Dang TN; Arseneault M; Ramassamy C
J Alzheimers Dis; 2010; 21(3):741-56. PubMed ID: 20634576
[TBL] [Abstract][Full Text] [Related]
5. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death.
Butterfield DA; Castegna A; Lauderback CM; Drake J
Neurobiol Aging; 2002; 23(5):655-64. PubMed ID: 12392766
[TBL] [Abstract][Full Text] [Related]
6. Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders.
Di Domenico F; Tramutola A; Butterfield DA
Free Radic Biol Med; 2017 Oct; 111():253-261. PubMed ID: 27789292
[TBL] [Abstract][Full Text] [Related]
7. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease.
Sayre LM; Zelasko DA; Harris PL; Perry G; Salomon RG; Smith MA
J Neurochem; 1997 May; 68(5):2092-7. PubMed ID: 9109537
[TBL] [Abstract][Full Text] [Related]
8. The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin.
Neely MD; Sidell KR; Graham DG; Montine TJ
J Neurochem; 1999 Jun; 72(6):2323-33. PubMed ID: 10349841
[TBL] [Abstract][Full Text] [Related]
9. Detoxification of cytotoxic alpha,beta-unsaturated aldehydes by carnosine: characterization of conjugated adducts by electrospray ionization tandem mass spectrometry and detection by liquid chromatography/mass spectrometry in rat skeletal muscle.
Aldini G; Granata P; Carini M
J Mass Spectrom; 2002 Dec; 37(12):1219-28. PubMed ID: 12489081
[TBL] [Abstract][Full Text] [Related]
10. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease.
Williams TI; Lynn BC; Markesbery WR; Lovell MA
Neurobiol Aging; 2006 Aug; 27(8):1094-9. PubMed ID: 15993986
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of protein-bound endogenous aldehydes. Chemical and immunochemical characterizations of configurational isomers of a 4-hydroxy-2-nonenal-histidine adduct.
Hashimoto M; Sibata T; Wasada H; Toyokuni S; Uchida K
J Biol Chem; 2003 Feb; 278(7):5044-51. PubMed ID: 12473681
[TBL] [Abstract][Full Text] [Related]
12. Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain.
Sultana R; Perluigi M; Butterfield DA
Free Radic Biol Med; 2013 Sep; 62():157-169. PubMed ID: 23044265
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4.
Montine KS; Olson SJ; Amarnath V; Whetsell WO; Graham DG; Montine TJ
Am J Pathol; 1997 Feb; 150(2):437-43. PubMed ID: 9033259
[TBL] [Abstract][Full Text] [Related]
14. Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD.
Reed TT; Pierce WM; Markesbery WR; Butterfield DA
Brain Res; 2009 Jun; 1274():66-76. PubMed ID: 19374891
[TBL] [Abstract][Full Text] [Related]
15. 4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease.
Montine KS; Kim PJ; Olson SJ; Markesbery WR; Montine TJ
J Neuropathol Exp Neurol; 1997 Aug; 56(8):866-71. PubMed ID: 9258256
[TBL] [Abstract][Full Text] [Related]
16. Michael addition-type 4-hydroxy-2-nonenal adducts in modified low-density lipoproteins: markers for atherosclerosis.
Uchida K; Toyokuni S; Nishikawa K; Kawakishi S; Oda H; Hiai H; Stadtman ER
Biochemistry; 1994 Oct; 33(41):12487-94. PubMed ID: 7918471
[TBL] [Abstract][Full Text] [Related]
17. Identification of 4-hydroxy-2-nonenal-histidine adducts that serve as ligands for human lectin-like oxidized LDL receptor-1.
Kumano-Kuramochi M; Shimozu Y; Wakita C; Ohnishi-Kameyama M; Shibata T; Matsunaga S; Takano-Ishikawa Y; Watanabe J; Goto M; Xie Q; Komba S; Uchida K; Machida S
Biochem J; 2012 Feb; 442(1):171-80. PubMed ID: 22077443
[TBL] [Abstract][Full Text] [Related]
18. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease.
Lovell MA; Ehmann WD; Mattson MP; Markesbery WR
Neurobiol Aging; 1997; 18(5):457-61. PubMed ID: 9390770
[TBL] [Abstract][Full Text] [Related]
19. Aldehydes from n-6 fatty acid peroxidation. Effects on aminophospholipids.
Guichardant M; Bernoud-Hubac N; Chantegrel B; Deshayes C; Lagarde M
Prostaglandins Leukot Essent Fatty Acids; 2002; 67(2-3):147-9. PubMed ID: 12324234
[TBL] [Abstract][Full Text] [Related]
20. Potential role of acrolein in neurodegeneration and in Alzheimer's disease.
Dang TN; Arseneault M; Murthy V; Ramassamy C
Curr Mol Pharmacol; 2010 Jun; 3(2):66-78. PubMed ID: 20302565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
